T1	Participants 61 125	patients with hepatitis B e antigen-negative chronic hepatitis B
T2	Participants 210 236	chronic hepatitis B (CHB).
T3	Participants 459 548	hirteen patients with HBeAg-negative CHB received peginterferon alfa-2a (180 microg/week)
T4	Participants 1497 1583	historical controls with HBeAg-negative CHB treated with 48 wk of pegylated interferon
